연구성과로 돌아가기

2024 연구성과별 연구자 정보 (1615 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Vogel, Arndt Vogel, A 1 Toronto Gen Hosp, Toronto, ON, Canada
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Chan, Stephen L. Chan, SL 2 Chines Univ Hongkong, Hong Kong, Peoples R China F-9149-2011 Chan, Stephen
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Furuse, Junji Furuse, J 3 Kyorin Univ, Sch Med, Mitaka, Tokyo, Japan
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Tak, Won Young Tak, WY 4 Kyungpook Natl Univ, Sch Med, Daegu, South Korea
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Masi, Gianluca Masi, G 5 Univ Pisa, Pisa, Italy
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Varela, Maria Varela, M 6 Cent Univ Hosp Asturias, Oviedo, Spain
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Kim, Jee Hyun Kim, JH 7 Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Tanasanvimon, Suebpong Tanasanvimon, S 8 Chulalongkorn Univ, Fac Med, Bangkok, Thailand
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Reig, Maria Reig, M 9 Univ Barcelona, Barcelona, Spain
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Dayyani, Farshid Dayyani, F 10 Univ Calif Irvine, Irvine, CA USA CAF-8867-2022 Dayyani, Farshid
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Makowsky, Mallory Makowsky, M 11 AstraZeneca, Gaithersburg, MD USA
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Marcovitz, Michelle Marcovitz, M 12 AstraZeneca, Gaithersburg, MD USA
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Negro, Alejandra Negro, A 13 AstraZeneca, Gaithersburg, MD USA
Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Abou-Alfa, Ghassan Abou-Alfa, G 14 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
Outcomes in patients with out-of-hospital cardiac arrest according to prehospital advanced airway management timing: a retrospective observational study Lee, Sang-Hun Lee, SH 1 0000-0003-4303-7375 Lee, Sang-Hun ryoo@knu.ac.kr;
페이지 이동: